Superworth

Sunshine Biopharma EPS SBFM

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2025
−$702.00
Latest quarter, Q2 FY25
−$164.00
Fiscal year 2024
−$17146.00

Sunshine Biopharma's earnings per share was −$702.00 over the twelve months to Jun 30, 2025.

In its latest quarter, Q2 FY25, it was −$164.00.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2024−$17146.00n/a
FY2023−$61078.00n/a
FY2022−$560000.00n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY25−$164.00n/a−$702.00
Q1 FY25−$88.00n/a−$9234.00
Q4 FY24−$262.00n/a−$17146.00
Q3 FY24−$188.00n/a−$36884.00
Q2 FY24−$8696.00n/a−$46840.00
Q1 FY24−$8000.00n/a−$38158.00
Q4 FY23−$20000.00n/a−$61078.00
Q3 FY23−$10144.00n/a−$465078.00
Q2 FY23−$14.00n/a−$486934.00
Q1 FY23−$30920.00n/a−$498920.00
Q4 FY22−$424000.00n/a−$560000.00
Q3 FY22−$32000.00n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Sunshine Biopharma's size, closest first, today.

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Sunshine Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.